Transthyretin Cardiac Amyloidosis in HFpEF

计划入组 287 人 · 首次发布于 2018 年 1 月 30 日

Exercise Training in Transthyretin Cardiac Amyloidosis

计划入组 40 人 · 首次发布于 2023 年 4 月 4 日

Subclinical Transthyretin Cardiac Amyloidosis in V122I TTR Carriers

计划入组 500 人 · 首次发布于 2022 年 8 月 5 日

Transthyretin Amyloidosis Therapy (HuidaGene)

TTR gene therapy (transthyretin amyloidosis)

CRISPR-Cas12 gene therapy (HG-PRECISE, Transthyretin Amyloidosis)

Cardiac Implants LLC

United States

CARDIAC DIMENSIONS PTY. LTD.

Australia

TEXAS CARDIAC ARRHYTHMIA RESEARCH FOUNDATION

United States

Rambam Hospital Pioneers CRISPR Gene Therapy Trial for Cardiac Amyloidosis

Dual Diagnosis of Aortic Stenosis and Cardiac Amyloidosis Linked to Higher Mortality Risk, Study Shows

FDA Approves BridgeBio's Attruby (acoramidis) for ATTR-CM